Fluffy, You just wrote a very thoughtful post and early in the morning I might add. Here is my contribution on this early am.
Abbott's Architect c8000 analyzers and Bayer's Advia analyzers all run colorimetric assays. Other brands also use the colorimetric format. Enzymes (which speed up chemical reactions) and colorimetric assays appear to have a close association. The following appears to be the applicable portion of BioCurex's serum RECAF patent that applies to colorimetric assays:
"10. A method as described in claim 4 wherein the antibody labeled with enzyme or AFP labeled with enzyme change the color of the biological specimen, and the identifying step includes the step of comparing the color of the biological specimen with a known color to determine the presence of cancer."
In previous SEC filings BioCurex has stated the following:
"BioCurex has developed a serum based cancer screening assay and has licensed certain aspects of the serum assay technology to Abbott Laboratories." "BioCurex retained all rights to its prototype format, a radio-immunoassay (RIA), .."
From the statements immediately above, it can be assumed that Abbott wisely licensed the aspects of BioCurex's serum assay technology that gives Abbott the right to use a serum RECAF colorimetric assay.
I think the below statement is one of the most intriguing parts of yesterday's press release:
"This large difference between cancers and normal patients not only allows the detection of smaller tumors, (as recently shown for breast cancers where we can now detect 90% of early stages I and II); but it is also a requirement for a ``yes/no' rapid test similar to a pregnancy test that could be used directly in the doctors' offices."
It is easy here to visualize a color test strip eventually being used in a primary care doctor's office as an early screening test for cancer.
In summary, I would like to point out that people who seem to always be "lucky" have been proven to have a lot to do with their so called luck. Research shows that those people take action which happens to result in good things happening to them. A direct analogy can be drawn to yesterday's press release. Obviously, BioCurex needed a new serum RECAF format to make it easier for big diagnostic companies to be attracted to their serum RECAF technology. So BioCurex designed one using a simple colorimetric format that easily can be run on most automated analyzers. Yesterday, BioCurex announced to the world that it is quite "feasible" to run simple RECAF assays on automated analyzers. In a way, putting pressure on Abbott to also announce the same thing. BioCurex, used the new colorimetic assay to produce the very high sensitivity and specificity stage I and II early breast cancer detection that was announced on April 11, 2006. So it is feasible and everyone including Abbott now knows it. We should expect Abbott's first milestone announcement shortly. kag
News 
Market Data 
Discover 
